凌晨三点高清免费观看|性吧 色婷婷精品综合一区久久|久久亚洲欧美熟女|国产精品国三级国产aⅴ|亚洲福利在线看国产精品|水蜜桃久久夜色精品国产|国产精品久久露脸|午夜男女无遮掩免费视频|我与旗袍老师疯狂床震|午夜无码免费视频一区二区,中文字幕人成乱码熟女69 ,欧美日韩另类综合中文字幕精品 ,91精品国产91久久久久

姓名：周蕓 性別：女 政治面貌：中共黨員

學(xué)歷：研究生 學(xué)位：博士

職稱(chēng)：主任醫(yī)師 博、碩導(dǎo)師：博導(dǎo)/碩導(dǎo)

本崗位工作年數(shù)：31年

研究方向：腎臟疾病基礎(chǔ)與臨床研究

榮譽(yù)稱(chēng)號(hào)：

國(guó)務(wù)院特殊津貼專(zhuān)家，國(guó)家級(jí)一流本科課程負(fù)責(zé)人，山西省教學(xué)名師，山西省學(xué)術(shù)技術(shù)帶頭人，山西省“三晉英才”拔尖骨干人才，山西省衛(wèi)計(jì)委百千萬(wàn)衛(wèi)生人才臨床高端領(lǐng)軍人才，山西省五一勞動(dòng)獎(jiǎng)?wù)芦@得者。

學(xué)術(shù)任職：

中國(guó)老年醫(yī)學(xué)會(huì)腎臟病分會(huì)常務(wù)委員，中國(guó)康復(fù)醫(yī)學(xué)會(huì)腎臟病康復(fù)專(zhuān)業(yè)委員會(huì)常務(wù)委員，中國(guó)研究型醫(yī)院學(xué)會(huì)血液凈化專(zhuān)業(yè)委員會(huì)常務(wù)委員，山西省醫(yī)師協(xié)會(huì)副會(huì)長(zhǎng)，山西省醫(yī)學(xué)會(huì)第七屆腎臟病學(xué)專(zhuān)業(yè)委員會(huì)候任主委，山西省醫(yī)師協(xié)會(huì)醫(yī)學(xué)人文專(zhuān)業(yè)委員會(huì)主任委員。

近五年承擔(dān)科研課題情況：

1.山西省中醫(yī)藥管理局科技創(chuàng)新團(tuán)隊(duì)項(xiàng)目，項(xiàng)目名稱(chēng)：中醫(yī)藥傳承防治慢性腎臟病創(chuàng)新團(tuán)隊(duì)，項(xiàng)目編號(hào)：zyytd2024015

2.山西省財(cái)政廳2023年支持公立醫(yī)院改革與高質(zhì)量發(fā)展示范項(xiàng)目，項(xiàng)目名稱(chēng)：腎臟病臨床與研究創(chuàng)新基地，項(xiàng)目編號(hào)：晉財(cái)社〔2023〕23號(hào)

3.山西省科技廳重點(diǎn)研發(fā)項(xiàng)目，項(xiàng)目名稱(chēng)：治療膿毒癥急性腎損傷臨床經(jīng)驗(yàn)方的醫(yī)療機(jī)構(gòu)制劑開(kāi)發(fā)與應(yīng)用，項(xiàng)目編號(hào)：202302130501011

4.山西省中醫(yī)藥科研項(xiàng)目，項(xiàng)目名稱(chēng)：中藥制劑調(diào)控脂肪酸氧化對(duì)膿毒癥腎損傷的治療作用及機(jī)制研究，項(xiàng)目編號(hào)：2023ZYY017。

5.山西中醫(yī)藥大學(xué)科技創(chuàng)新團(tuán)隊(duì)項(xiàng)目，項(xiàng)目名稱(chēng)：針?biāo)幗Y(jié)合防治慢性腎臟病創(chuàng)新團(tuán)隊(duì)，項(xiàng)目編號(hào)：2022TD2004

6.中央引導(dǎo)地方科技發(fā)展資金項(xiàng)目（科技創(chuàng)新基地建設(shè)） 項(xiàng)目名稱(chēng)：山西省疾病模型動(dòng)物研發(fā)創(chuàng)新基地，項(xiàng)目編號(hào):晉衛(wèi)規(guī)劃函[2021]123號(hào)

代表性論著及近五年的代表性論文（限10項(xiàng)以?xún)?nèi)）：

1.Zhang Q, Zhao Y, Luo Y, Guo S, Hou H, Han X,Zhou Y*. Urinary exosomal miRNA-451a can be used as a potential noninvasive biomarker for diagnosis, reflecting tubulointerstitial damage and therapeutic response in IgA nephropathy. Ren Fail. 2024 Dec;46(1):2319326. doi: 10.1080/0886022X.2024.2319326. Epub 2024 Feb 20. PMID: 38379319. (IF=3.0醫(yī)學(xué)3區(qū))

2.Gao T, Gao S, Wang H, Wang S, Li L, Hu J, Yan S, Zhang R,Zhou Y*, Dong H. Garlic ameliorates atherosclerosis by regulating ferroptosis pathway: an integrated strategy of network pharmacology, bioinformatic and experimental verification. Front Pharmacol. 2024 Jul 23;15:1388540. doi: 10.3389/fphar.2024.1388540. PMID: 39108744. (IF=4.4醫(yī)學(xué)2區(qū))

3.Gao S, Gao T, Li L, Wang S, Hu J, Zhang R,Zhou Y*, Dong H. Exploring the therapeutic potential of garlic in alcoholic liver disease: a network pharmacology and experimental validation study. Genes Nutr. 2024 Jul 23;19(1):13. doi: 10.1186/s12263-024-00748-3. PMID: 39044161. (IF=3.3醫(yī)學(xué)3區(qū))

4.Xi H, Li X,Zhou Y*, Sun Y. The Regulatory Effect of the Paraventricular Nucleus on Hypertension. Neuroendocrinology. 2024;114(1):1-13. doi:10.1159/000533691.PMID: 37598678. (IF=3.2醫(yī)學(xué)2區(qū))

5.Chen P, Mao M, Wang C, Zhang X, Zhao X, Gao Y, Luo Y,Zhou Y*. Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience. Front Endocrinol (Lausanne). 2023(15):14:1044782. doi: 10.3389/fendo. PMID: 36875477. (IF=3.9醫(yī)學(xué)2區(qū))

6.Wang H, Gao T, Zhang R, Hu J, Wang Y, Wei J,Zhou Y*, Dong H*. The intellectual base and global trends in contrast-induced acute kidney injury: a bibliometric analysis. Ren Fail. 2023,45(1):2188967. doi: 10.1080/0886022X.2023.2188967. PMID: 36929915. (IF=3.0醫(yī)學(xué)3區(qū))

7.Wu G, Han Y, Zhao L, Zhang H, Fan X, Li W, Che X*,Zhou Y*. Reversible cardiac function and left ventricular hypertrophy in a Chinese man with mitochondrial myopathy: a case report. BMC Cardiovasc Disord. 2023,23(1):464. doi: 10.1186/s12872-023-03444-z. PMID: 37715114. (IF=2.0醫(yī)學(xué)3區(qū))

8.Xia M, Zhao F, Zhang Y, Zheng Z,Zhou Y*, Liu T*. Identification of diagnostic markers and immune cell infiltration characteristics in antineutrophil cytoplasmic antibody-associated vasculitis by weighted gene co-expression network analysis. Eur J Med Res. 2022,27(1):37. doi: 10.1186/s40001-022-00666-3. PMID: 35246248. (IF=2.8醫(yī)學(xué)3區(qū))

9.Wang Y, Tian J, Mi Y, Ren X, Lian S, Kang J, Wang J, Zang H, Wu Z, Yang J, Qiao X, Zhou X, Wang G,Zhou Y*, Li R*. Experimental study on renoprotective effect of intermedin on diabetic nephropathy. Mol Cell Endocrinol. 2021(15):528:111224. doi: 10.1016/j.mce.2021.111224. PMID: 33675865. (IF=3.8醫(yī)學(xué)2區(qū))

10.Wang Y, Mi Y, Tian J, Qiao X, Su X, Kang J, Wu Z, Wang G, Zhou X,Zhou Y*, Li R*. Intermedin Alleviates Renal Ischemia-Reperfusion Injury and Enhances Neovascularization in Wistar Rats. Drug Des Devel Ther. 2020,10(14):4825-4834. doi: 10.2147/DDDT.S253019. PMID: 33204068. (IF=4.2醫(yī)學(xué)2區(qū))